Log In
BCIQ
Print this Print this
 

Idalopirdine (Lu AE58054)

  Manage Alerts
Collapse Summary General Information
Company H. Lundbeck A/S
DescriptionSelective serotonin (5-HT6) receptor antagonist
Molecular Target Serotonin (5-HT6) receptor
Mechanism of ActionSerotonin (5-HT6) receptor antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation U.S. - Fast Track (Treat Alzheimer's disease (AD))
PartnerOtsuka Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$200.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/14/2011

Undisclosed

$200.0M

Undisclosed

Get a free BioCentury trial today